<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01010100</url>
  </required_header>
  <id_info>
    <org_study_id>10139</org_study_id>
    <secondary_id>PREDIAP</secondary_id>
    <nct_id>NCT01010100</nct_id>
  </id_info>
  <brief_title>Prevent/Delay Development of Type 2 Diabetes in Subjects With Impaired Glucose Homeostasis Treated With Acarbose in Primary Care</brief_title>
  <official_title>A Multi-centre, Parallel, Double-blind, Randomised and Placebo Controlled Spanish Study, to Prevent or Delay the Development of Type 2 Diabetes in Subjects With Impaired Glucose Homeostasis Treated With Acarbose in Primary Care (PREDIAP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if the administration of small doses of Acarbose can
      prevent or delay the appearance of Type 2 Diabetes Mellitus in a population of subjects with
      prediabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2000</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The principal objective was to determine if the administration of small doses of Acarbose could prevent or delay the appearance of Type 2 DM in a population of subjects with impaired glucose homeostasis.</measure>
    <time_frame>The main criterion for the evaluation of the primary objective was the proportion of diabetic subjects after three years of treatment and another time after three months of wash-out with placebo.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Regression to the normality (NO impaired glucose homeostasis)</measure>
    <time_frame>Proportion of subjects that had regressed to normality after three years of treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the cardiovascular risk markers (microalbuminuria, triglycerides, fasting glycaemia, after overload glycaemia, HbA1c, C-peptide, insulinemia)</measure>
    <time_frame>Three years and three months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of blood pressure</measure>
    <time_frame>Three years and three months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of lipid profile</measure>
    <time_frame>Three years and three months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of anthropometric measurements</measure>
    <time_frame>Three years and three months. (BMI)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The appearance or progression of cardiovascular events: angina, myocardial infarction, cerebrovascular accident, congestive heart failure, peripheral vascular disease, revascularisation procedure</measure>
    <time_frame>Time until the appearance or progression of cardiovascular episodes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delay in the conversion to diabetes mellitus</measure>
    <time_frame>Time until the confirmation of the diagnosis of Diabetes Mellitus</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">204</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acarbose (Glucobay, BAYG5421)</intervention_name>
    <description>50 mg TID</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>50 mg TID</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 40 and &lt; 75 years old

          -  Men and women

          -  Able to give voluntary informed consent

          -  Existence of one or more of the following risk factors:

          -  Body Mass Index (BMI) &gt; 27 mg/Kg2

          -  One or more family members with diabetes determined by anamnesis.

          -  Personal antecedents of previous blood glucose anomalies (gestational diabetes
             reverted after the lactation time, before-during surgical stress, fasting glycaemia &gt;
             110 mg/dL (6,1 mM) and &lt; 126 mg/dL (7 mM) registered in the Clinical History during
             the last 3 years, etc.)

          -  Previous consumption of drugs with hyperglycaemic capacity for a period of 3 months
             continuously or more than 6 months discontinuously

        Exclusion Criteria:

          -  Type 2 DM

          -  Pregnancy during the study

          -  Nursing women

          -  Major debilitating (e.g. collagen vascular diseases, failure of major organ,
             psychosis, severe infections, neutropenia, BMI &lt; 20 mg/Kg2)

          -  Subjects taking a prohibited drug (see protocol)

          -  Subjects taking drugs that can impair intestinal motility and/or carbohydrate
             absorption (i.e. cholestyramine, neomycin)

          -  Recent cardiovascular events (within last 6 months) such as myocardial infarction,
             cerebrovascular accident, congestive heart failure

          -  Serum creatinine &gt; 2 mg/Dl

          -  Fasting triglycerides &gt; 10 mm/L (&gt; 885 mg/dL)

          -  AST elevation &gt; 2.5 times above the upper limit of normal

          -  Subjects with hyper/hypothyroidism non compensated

          -  Subjects with documented gastrointestinal diseases that are likely to be associated
             with abnormal intestinal motility or altered absorption of nutrients (e.g.
             gastroparesia, malabsorption syndrome, chronic diarrhoea states, enteropathies,
             inflammatory bowel diseases, partial intestinal obstruction, large hernias)

          -  Subjects with any emotional disorder or substance abuse (e.g. severe depression,
             alcohol or drug abuse)

          -  Hypersensitivity to Acarbose
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Agost</city>
        <state>Alicante</state>
        <zip>03698</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Crevillente</city>
        <state>Alicante</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novelda</city>
        <state>Alicante</state>
        <zip>03660</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Vicente del Raspeig</city>
        <state>Alicante</state>
        <zip>03690</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trobajo del Camino</city>
        <state>Le√≥n</state>
        <zip>24010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Begonte</city>
        <state>Lugo</state>
        <zip>27373</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Villalba</city>
        <state>Lugo</state>
        <zip>27800</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Camas</city>
        <state>Sevilla</state>
        <zip>41900</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Constanti</city>
        <state>Tarragona</state>
        <zip>43120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cornudella</city>
        <state>Tarragona</state>
        <zip>43360</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>El Morell</city>
        <state>Tarragona</state>
        <zip>43760</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Falset</city>
        <state>Tarragona</state>
        <zip>43730</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Les Borges del Camp</city>
        <state>Tarragona</state>
        <zip>43350</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <zip>43201</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <zip>43202</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <zip>43203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tortosa</city>
        <state>Tarragona</state>
        <zip>43500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vinebre</city>
        <state>Tarragona</state>
        <zip>43729</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alicante</city>
        <zip>03007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tarragona</city>
        <zip>43005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tarragona</city>
        <zip>43006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2009</study_first_submitted>
  <study_first_submitted_qc>November 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2009</study_first_posted>
  <last_update_submitted>December 23, 2010</last_update_submitted>
  <last_update_submitted_qc>December 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Therapeutic Area Head</name_title>
    <organization>Bayer HealthCare AG</organization>
  </responsible_party>
  <keyword>Metabolic Disease</keyword>
  <keyword>IGT Impaired Glucose Tolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acarbose</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

